A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001714-24

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

1) To evaluate the efficacy of BTA798 in preventing HRV infection 2) To evaluate the efficacy of BTA798 in preventing upper respiratory tract illness.


Critère d'inclusion

  • BTA798 is an investigational drug being developed as a potential agent for treatment and prevention of the common cold

Liens